Health Condition 1: I10-I16- Hypertensive diseases
Conditions
Interventions
Intervention1: Benidipine: Group B: Participants would
receive Benidipine
Monotherapy of 4 mg/day
orally in morning for 90 days.
Control Intervention1: Amlodipine: Group A: Participants would
receive
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: 1.Newly diagnosed hypertensive patients as per Indian Society of Hypertension latest guidelines visiting the Medicine OPD. 2.Patients of either sex between 30 and 75 years of age. 3.Patients willing to join the study after giving the written informed consent.
Exclusion criteria
Exclusion criteria: 1.Patients diagnosed with secondary hypertension. 2.Patients with pre-existing cardiovascular complications (e.g., stroke, congestive heart failure). 3.Patients on concomitant medications known to significantly interact with calcium channel blockers (CCBs), such as non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, CNS stimulants. 4.Patients with severe renal, hepatic, or other systemic diseases affecting vital organ function. 5.Patients presenting with pedal edema, hypoproteinemia or anemia at baseline. 6.Pregnant or lactating women. 7.Patients with known contraindications or hypersensitivity to amlodipine or benidipine. 8.Patients unwilling to adhere to the study protocol or provide written consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare reduction in SBP and DBP between Benidipine and AmlodipineTimepoint: Baseline,4 weeks,8 weeks,12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare proportion of patients achieving target BP less than 130upon85 mmHgTimepoint: Baseline, 12weeks;To compare incidence of adverse drug reactionsTimepoint: Baseline,4 weeks,8 weeks,12 weeks | — |
Countries
India
Contacts
Public ContactDr Abhinav Dhiman
Government Medical College, Amritsar
Outcome results
None listed